抗真菌藥物市場規模、佔有率、成長分析、按藥物類型、按治療適應症、按類型、按給藥途徑、按配銷通路、按地區 - 行業預測，2025-2032 年

2023 年全球抗真菌藥物市場規模為 149 億美元，預計將從 2024 年的 155 億美元成長到 2032 年的 212.1 億美元，預測期內（2025-2032 年）的複合年成長率為 4.0%。成長%。

由於真菌感染疾病的盛行率不斷上升以及對有效治療的需求不斷增加，抗真菌藥物市場預計將顯著成長。藥物發現和開發過程的重大進展以及抗真菌研究的大量投資預計將增加市場活力。低度開發和發展中地區的新興市場對於醫療保健提供者來說意味著豐厚的商機。然而，抗真菌抗藥性和可用藥物範圍有限等挑戰可能會長期限制市場擴張。總體而言，儘管存在潛在障礙，但不斷成長的需求、技術進步和研究投資表明，未來幾年研究市場的前景光明。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術進步
• 貿易分析
• 客戶和購買標準分析
• 原料分析

抗真菌劑市場規模（按藥物類型）

• 市場概況
• 系統性Azole和Polyenes
• 外用Azole和Polyenes
• 系統性Echinocandins和抗代謝藥物
• 其他

抗真菌劑市場規模（按治療適應症）

• 市場概況
• 皮膚絲狀菌症
• 念珠菌症
• 麴菌症
• 其他

抗真菌劑市場規模（按類型）

• 市場概況
• 處方箋
• 場外交易（OTC）

抗黴菌劑市場規模（依給藥途徑）

• 市場概況
• 口服
• 局部的
• 腸外

抗真菌劑市場規模（按分銷管道分類）

• 市場概況
• 醫院藥房
• 零售藥局和藥局
• 網路藥局

抗真菌藥物市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Abbott（USA）
• Bayer AG（Germany）
• GSK plc（UK）
• Merck & Co., Inc.（USA）
• Cadila Pharmaceuticals（India）
• Glenmark Pharmaceuticals（India）
• SCYNEXIS, Inc.（USA）
• Astellas Pharma Inc.（Japan）
• Arcadia Consumer Healthcare（USA）
• Novartis AG（Switzerland）
• Pfizer Inc.（USA）
• Leadiant Biosciences, Inc.（USA）
• Sun Pharmaceutical Industries Ltd.（India）
• Viatris Inc.（USA）
• Sanofi（France）
• Gilead Sciences, Inc.（USA）
• Apotex Inc.（Canada）
• Aurobindo Pharma Limited（India）
• Cipla Inc.（India）
• Dr. Reddy's Laboratories Ltd.（India）

結論和建議

Global Antifungal Agents Market size was valued at USD 14.9 billion in 2023 and is poised to grow from USD 15.5 billion in 2024 to USD 21.21 billion by 2032, growing at a CAGR of 4.0% during the forecast period (2025-2032).

The antifungal agents market is poised for substantial growth, driven by the rising prevalence of fungal infections and an increasing demand for effective treatments. Significant advancements in drug discovery and development processes are expected to enhance market dynamics, alongside robust investments in antifungal research. Emerging markets in underdeveloped and developing regions present lucrative opportunities for providers. However, challenges such as antifungal resistance and the limited spectrum of available agents could pose constraints on long-term market expansion. Overall, the combination of growing demand, technological advancements, and investment in research suggests a positive outlook for the antifungal agents market in the coming years, despite the potential hurdles that may arise.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antifungal Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antifungal Agents Market Segmental Analysis

Global Antifungal Agents Market is segmented by Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel and region. Based on Drug Type, the market is segmented into Systemic Azoles & Polyenes, Topical Azoles & Polyenes, Systemic Echinocandins & Antimetabolics and Others. Based on Therapeutic Indication, the market is segmented into Dermatophytosis, Candidiasis, Aspergillosis and Others. Based on Type, the market is segmented into Prescription and Over the counter (OTC). Based on Route of Administration, the market is segmented into Oral, Topical and Parenteral. Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies & Drug Stores and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antifungal Agents Market

The global antifungal agents market is primarily driven by the rising incidence of fungal infections, which can be attributed to the widespread antibiotic resistance and the increasing prevalence of chronic infectious diseases. As more patients succumb to fungal infections due to these factors, there is an anticipated surge in the demand for antifungal agents. This escalation highlights the critical need for effective treatments to combat these infections, further propelling the market's growth. With healthcare providers seeking reliable solutions, the antifungal agents market is poised for significant expansion in response to these pressing health challenges.

Restraints in the Global Antifungal Agents Market

The global antifungal agents market faces significant limitations due to the rising phenomenon of antifungal resistance. As fungal pathogens evolve and become increasingly resistant to commonly prescribed antifungal treatments, the effectiveness of these agents diminishes, leading to a concerning epidemic of resistance. This situation poses a serious threat to the market's growth potential, as many antifungal medications may become ineffective in treating infections, ultimately impacting clinical outcomes and increasing the burden on healthcare systems. If left unaddressed, this growing challenge could hinder innovation and development of new antifungal treatments, thereby stalling market expansion in the foreseeable future.

Market Trends of the Global Antifungal Agents Market

The Global Antifungal Agents market is witnessing a notable trend towards personalized medicine, with vendors increasingly partnering with biotech firms to create tailored treatments for diverse fungal infections. By leveraging advancements in personalized approaches, such as precision diagnostics and targeted therapies, antifungal agents can enhance efficacy and improve patient outcomes. This collaboration not only addresses the unique genetic and clinical profiles of patients but also offers lucrative revenue opportunities for companies willing to innovate. As awareness of personalized medicine grows, stakeholders in the antifungal sector are positioned to capitalize on this trend, driving market growth and elevating treatment standards globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement
• Trade Analysis
• Customer & Buying Criteria Analysis
• Raw Material Analysis

Global Antifungal Agents Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Systemic Azoles & Polyenes
• Topical Azoles & Polyenes
• Systemic Echinocandins & Antimetabolics
• Others

Global Antifungal Agents Market Size by Therapeutic Indication & CAGR (2025-2032)

• Market Overview
• Dermatophytosis
• Candidiasis
• Aspergillosis
• Others

Global Antifungal Agents Market Size by Type & CAGR (2025-2032)

• Market Overview
• Prescription
• Over the counter (OTC)

Global Antifungal Agents Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Topical
• Parenteral

Global Antifungal Agents Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospitals Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

Global Antifungal Agents Market Size & CAGR (2025-2032)

• North America (Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Abbott (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Pharmaceuticals (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SCYNEXIS, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arcadia Consumer Healthcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leadiant Biosciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apotex Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations